Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Flushed: LAIV Viral Shedding Study
NCT03104790Phase 4Completed
- Sponsor
- UK Health Security Agency
- Start
- Oct 2017
- Primary completion
- Mar 2018
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 4, open-label trial of live attenuated influenza vaccine in influenza (2 arms), sponsored by UK Health Security Agency. Primary endpoint: Virus shedding at Day 21. Started Oct 2017; status: completed.
02
Drugs
live attenuated influenza vaccine
03
Conditions
influenza
Beyond the preview
Go deeper on NCT03104790.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03104790.